Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank

Journal of the American Heart Association 2026 Open access

Read full text
Authors: Richard Kazibwe, Christopher L. Schaich, Parag Anilkumar Chevli, Jeff Kingsley, Saeid Mirzai, Juliana H. Namutebi, Muhammad Imtiaz Ahmad, Anurag Mehta, Harpreet Bhatia, Mitchell Paukner, Rishi Rikhi, Erin D. Michos
+1 more Michael D. Shapiro
DOI: 10.1161/jaha.125.042361
Cited by: 2
References: 47

Abstract

Background Insulin resistance (IR) and lipoprotein(a), Lp(a), are established contributors to cardiovascular disease (CVD) risk. Whether IR modifies the association between Lp(a) and CVD in primary prevention remains uncertain. Methods This prospective cohort study included UK Biobank participants without baseline CVD. IR at enrollment was assessed using the triglyceride‐glucose index (TyG). The primary outcome was first major adverse cardiovascular event, defined as peripheral arterial disease, coronary artery disease, myocardial infarction, ischemic stroke, or cardiovascular death. Cox models estimated adjusted hazard ratios (aHRs) with 95% CIs for log‐transformed Lp(a) and TyG, adjusting for each other. Lp(a) was categorized as

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health HIV-related health complications and treatments Atherosclerosis and Cardiovascular Diseases

Publication details

Journal / source
Journal of the American Heart Association
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
15
Issue
4
Pages
e042361–e042361
Publication date
11 February 2026
Language
EN